{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:37:14Z","timestamp":1762180634709,"version":"build-2065373602"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of Nanjing University of Chinese Medicine","award":["XZR2023075"],"award-info":[{"award-number":["XZR2023075"]}]},{"name":"The Hospital Management Research of Jiangsu Province","award":["JSYGY-3-2023-618"],"award-info":[{"award-number":["JSYGY-3-2023-618"]}]},{"name":"Medical Science and Technology Development Foundation of Nanjing","award":["YKK22095"],"award-info":[{"award-number":["YKK22095"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03727-1","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:49:33Z","timestamp":1762177773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intracavitary infusion of FOLactis Lactobacillus leads to disappearance of MPE in patient with advanced lung adenocarcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Mingzhen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"10","key":"3727_CR1","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.amjmed.2022.04.017","volume":"135","author":"S Gayen","year":"2022","unstructured":"Gayen S. Malignant pleural effusion: presentation, diagnosis, and management. Am J Med. 2022;135(10):1188\u201392.","journal-title":"Am J Med"},{"issue":"3","key":"3727_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3892\/ijo.2021.5174","volume":"58","author":"D He","year":"2021","unstructured":"He D, Ding R, Wen Q, et al. Novel therapies for malignant pleural effusion: anti-angiogenic therapy and immunotherapy (Review). Int J Oncol. 2021;58(3):359\u201370.","journal-title":"Int J Oncol"},{"issue":"11","key":"3727_CR3","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/resp.13812","volume":"25","author":"KY Chiang","year":"2020","unstructured":"Chiang KY, Ho JCM, Chong P, et al. Role of early definitive management for newly diagnosed malignant pleural effusion related to lung cancer. Respirology. 2020;25(11):1167\u201373.","journal-title":"Respirology"},{"key":"3727_CR4","first-page":"2950751","volume":"2020","author":"L Ferreiro","year":"2020","unstructured":"Ferreiro L, Suarez-Antelo J, Alvarez-Dobano JM et al. Malignant pleural effusion: diagnosis and management. Can Respir J. 2020;2020: 2950751.","journal-title":"Can Respir J"},{"issue":"11","key":"3727_CR5","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1097\/JTO.0000000000000673","volume":"10","author":"WE Eberhardt","year":"2015","unstructured":"Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515\u201322.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3727_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/1759-7714.13238","volume":"11","author":"K Nie","year":"2020","unstructured":"Nie K, Zhang Z, You Y, et al. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer. Thorac Cancer. 2020;11(1):8\u201314.","journal-title":"Thorac Cancer"},{"key":"3727_CR7","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.2147\/OTT.S184030","volume":"11","author":"X Song","year":"2018","unstructured":"Song X, Chen D, Guo J, et al. Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer. Onco Targets Ther. 2018;11:8421\u20136.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"3727_CR8","doi-asserted-by":"publisher","first-page":"e1554969","DOI":"10.1080\/2162402X.2018.1554969","volume":"8","author":"P Murthy","year":"2019","unstructured":"Murthy P, Ekeke CN, Russell KL, et al. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology. 2019;8(4):e1554969.","journal-title":"Oncoimmunology"},{"issue":"1","key":"3727_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/cei.12845","volume":"186","author":"C Hu","year":"2016","unstructured":"Hu C, Zhang Y, Wang T, et al. Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer. Clin Exp Immunol. 2016;186(1):106\u201314.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"3727_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.lungcan.2007.07.009","volume":"58","author":"K Yoshida","year":"2007","unstructured":"Yoshida K, Sugiura T, Takifuji N, et al. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer (Amsterdam, Netherlands). 2007;58(3):362\u20138.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"3727_CR11","doi-asserted-by":"publisher","first-page":"760683","DOI":"10.3389\/fimmu.2021.760683","volume":"12","author":"X Li","year":"2021","unstructured":"Li X, Wu G, Chen C, et al. Intrapleural injection of anti-PD1 antibody: a novel management of malignant pleural effusion. Front Immunol. 2021;12:760683.","journal-title":"Front Immunol"},{"issue":"1","key":"3727_CR12","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1038\/s41467-022-35130-7","volume":"13","author":"J Zhu","year":"2022","unstructured":"Zhu J, Ke Y, Liu Q, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun. 2022;13(1):7466.","journal-title":"Nat Commun"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03727-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03727-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03727-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:49:33Z","timestamp":1762177773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03727-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3727"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03727-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by ethics committee of Comprehensive Cancer Center of Drum Tower Hospital of Nanjing University and Drum Tower Hospital of Nanjing University. The patients\/participants provided their written informed consent to participate in this study and agree to publish the relevant content. Registry and the Registration No. of the study\/trial: N\/A. Animal Studies: N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2016"}}